Stem Cell Beauty: The Online Shop Revolutionizing the Beauty Industry

Los Angeles, California (PRWEB) September 03, 2014

Stem Cell technology is the future; looking younger and better without plastic surgery is here now. Stem Cell Beautys debut product line StemLife is spearheading the current beauty renaissance. Among websites that provide stem cell beauty products, Stem Cell Beauty is in a league of its own.

Science is always advancing, why shouldn't your beauty products? questions Albert Faleski, Director of Operations at StemCellBeauty.com.

Most products on the shelves are outdated, whereas we take a different approach to find a formula that works with your body, reinvigorating your own stem cells to provide actual results.

The science behind StemLife is nothing short of groundbreaking. Its trademarked FixT Technology was achieved through reverse engineering to understand how the body maintains and heals itself with our own endogenous combinations of adult stem cells. With this knowledge they developed a means to mimic the natural stem cell processes in our body. Unlike other beauty brands, StemLife uses specific combinations of stem cell types, each cultured under specific state-dependent conditions, using cell types and states that are ideal for the particular tissue. It then creates a set of molecules from multiple stem cell types that is complete and fully formed, rendering maximum benefit and efficiency. This approach of stem cell skin care is extremely unique.

Other leading stem cell-based beauty companies use simpler technology where one stem cell type is chosen to make their molecules. This one-size fits all approach is not efficient and lacks the complexity of StemLifes FixT technology. Some companies mash the cells without allowing their molecules to fully process, which again leads to underachieving results. Many of the largest companies have made no attempt to use new science to formulate better products, providing their customers with over-priced serums proven to be archaic.

StemLifes cutting edge formula is shaping the future of hair regrowth as well, providing an ultramodern solution to those looking to slow the hands of time. Their most popular product, The Advanced Hair Treatment for Women, is essentially the hidden gem the world has been waiting for.

Its popularity stems back to the fact that it actually works. Faleski explained.

Were not big on gimmicks. We prefer showing our customer actual people who have had actual results with our products. After seeing life-changing hair growth with their own eyes, we are confident new customers will try it and have amazing results of their own. The Advanced Hair Treatment for Women is an incredible product that sells itself.

StemLifes most interesting product to date is the Natural Lash & Brow Lash Extend. This product boasts ingredients that are formulated to generate eyelash growth. In a market where eyelash extensions have been the go-to fix for longer lashes, being able to naturally grow them is a revolutionary concept.

See original here:
Stem Cell Beauty: The Online Shop Revolutionizing the Beauty Industry

Transplanted stem cells help prevent bladder fibrosis after spinal cord injury

PUBLIC RELEASE DATE:

3-Sep-2014

Contact: Robert Miranda cogcomm@aol.com Cell Transplantation Center of Excellence for Aging and Brain Repair

Putnam Valley, NY. (Sept. 3, 2014) A team of researchers from Korea and Canada have found that transplantation of B10 cells (a stable immortalized human bone marrow derived mesenchymal stem cell line; B10 hMSC) directly into the bladder wall of mice modeled with spinal cord injury (SCI) helped inhibit the development of bladder fibrosis and improved bladder function by promoting the growth of smooth muscle cells in the bladder.

The study will be published in a future issue of Cell Transplantation and is currently freely available on-line as an unedited early e-pub at: http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-CT-1227_Lee.

Spinal cord injury (SCI) can cause severe lower urinary tract dysfunction and conditions such as overactive bladder, urinary retention and increased bladder thickness and fibrosis. HMSCs, multipotent cells that can differentiate into a variety of cell types, including bone cells, cartilage cells, and fat cells, have been transplanted into injured spinal cords to help patients regain motor function.

In this study, mice receiving the B10 hMSCs injected directly into the bladder wall experienced improved bladder function while an untreated control group did not.

"Human MSCs can secrete growth factors," said study co-author Seung U. Kim of the Division of Neurology at the University of British Columbia Hospital, Vancouver, Canada. "In a previous study, we showed that B 10 cells secrete various growth factors including hepatocyte growth factor (HGF) and that HGF inhibits collagen deposits in bladder outlet obstructions in rats more than hMSCs alone. In this study, the SCI control group that did not receive B10 cells showed degenerated spinal neurons and did not recover. The B10-injected group appeared to have regenerated bladder smooth muscle cells."

Four weeks after the onset of SCI, the treatment group received the B10 cells transplanted directly into the bladder wall. To track the transplanted B10 cells via magnetic resonance imaging (MRI), the researchers labeled them with fluorescent magnetic particles.

"HGF plays an essential role in tissue regeneration and angiogenesis and acts as a potent antifibrotic agent," explained Kim.

Here is the original post:
Transplanted stem cells help prevent bladder fibrosis after spinal cord injury

Research in rodents suggests potential for 'in body' muscle regeneration

PUBLIC RELEASE DATE:

2-Sep-2014

Contact: Karen Richardson krchrdsn@wakehealth.edu 336-716-4453 Wake Forest Baptist Medical Center

Winston-Salem, N.C. Sept. 2, 2014 What if repairing large segments of damaged muscle tissue was as simple as mobilizing the body's stem cells to the site of the injury? New research in mice and rats, conducted at Wake Forest Baptist Medical Center's Institute for Regenerative Medicine, suggests that "in body" regeneration of muscle tissue might be possible by harnessing the body's natural healing powers.

Reporting online ahead of print in the journal Acta Biomaterialia, the research team demonstrated the ability to recruit stem cells that can form muscle tissue to a small piece of biomaterial, or scaffold that had been implanted in the animals' leg muscle. The secret to success was using proteins involved in cell communication and muscle formation to mobilize the cells.

"Working to leverage the body's own regenerative properties, we designed a muscle-specific scaffolding system that can actively participate in functional tissue regeneration," said Sang Jin Lee, Ph.D., assistant professor of regenerative medicine and senior author. "This is a proof-of-concept study that we hope can one day be applied to human patients."

The current treatment for restoring function when large segments of muscle are injured or removed during tumor surgery is to surgically move a segment of muscle from one part of the body to another. Of course, this reduces function at the donor site.

Several scientific teams are currently working to engineer replacement muscle in the lab by taking small biopsies of muscle tissue, expanding the cells in the lab, and placing them on scaffolds for later implantation. This approach requires a biopsy and the challenge of standardizing the cells.

"Our aim was to bypass the challenges of both of these techniques and to demonstrate the mobilization of muscle cells to a target-specific site for muscle regeneration," said Lee.

Most tissues in the body contain tissue-specific stem cells that are believed to be the "regenerative machinery" responsible for tissue maintenance. It was these cells, known as satellite or progenitor cells, that the scientists wanted to mobilize.

Read the rest here:
Research in rodents suggests potential for 'in body' muscle regeneration

Reneuron on track for clinical milestones as studies get underway

ReNeuron Group Quote more

Price: 3.62

Chg: -0.19

Chg %: -4.87%

Date: 16:38

Stem cell therapy group Reneuron said it remains on track with the first patients having been dosed in two its clinical trials.

The phase II trial for the ReN001 cell therapy candidate for stroke disability and the phase I trail for ReN009 cell therapy candidate for critical limb ischaemia have both begun.

The ReN001 trial is on course to have generated six month follow-up data by the end of 2015, while ReN009 study should give results in the first half of next year.

Chief executive officer (CEO) Michael Hunt said that Reneuron's core therapeutic programmes remain on track towards "further important clinical milestones" over the next 18 months.

"In particular, the commencement of dosing of patients in two new clinical trials, in stroke and limb ischaemia, marks another significant step in Reneuron's evolution into a fully-fledged clinical development business and a leading player in the increasingly exciting field of cell therapy and regenerative medicine," Hunt said.

Read the original post:
Reneuron on track for clinical milestones as studies get underway

PM Modi meets Nobel prize winner Yamanaka, discusses treatment of sickle cell anaemia remedy

KYOTO: Prime Minister Narendra Modi Sunday discussed cooperation with Japan to combat sickle cell anaemia that is prevalent in India's tribal regions, an official said.

Modi met Shinya Yamanaka, Japan's stem cell pioneer and 2012 Nobel Prize winner, at Kyoto University and discussed treatment of the disease.

They discussed the "possibilities of sickle cell anaemia cure" and "prospects of cooperation among Indian and Japanese institutes", tweeted an external affairs ministry spokesman.

"The prime minister expressed concern over the prevalence of sickle cell anaemia, especially among tribal communities across India," a statement by the Indian government said.

Sickling decreases the cells' flexibility and results in a risk of various life threatening complications. It mostly occurs in regions where malaria is rampant.

"The prime minister urged Yamanaka to work towards a cure for this," the statement said.

Yamanaka said there were currently no Indian researchers at his institute, the Centre for iPS Cell Research and Application, and "he would like Indian scientists to conduct research at the institute".

Stay updated on the go with The Times of Indias mobile apps. Click here to download it for your device.

Go here to read the rest:
PM Modi meets Nobel prize winner Yamanaka, discusses treatment of sickle cell anaemia remedy

In Japan, Modi discusses sickle cell treatment with Nobel laureate

Modi talks with Nobel Laureate Prof Yamanaka about treatment of sickle cell anaemia. Photograph: MEA/Facebook

Japan on Sunday agreed to work with India in developing a treatment for the sickle cell anaemia after Prime Minister Narendra Modi sought help for finding remedy to the deadly disease commonly found among tribals in India.

Modi, who has been keenly looking for a remedy to the disease since his days as the chief minister of Gujarat, discussed the issue with Nobel Prize winner for Medicine (2012) S Yamanaka when he visited the Kyoto University.

The PM, on the second day of his tour, raised the issue during his visit to the stem cell research facility and discussed whether Japan could be of help in this regard. Yamanaka is the director of the university.

"I wanted to understand stem cell research because cultural heritage matters as much to me as scientific heritage. I want to integrate both to make India a developed country. It was a good opportunity for me," Modi said.

The PM discussed the possibility of cooperation in finding a treatment for the disease, said External Affairs Ministry spokesman Syed Akbaruddin.

Sources said the Japanese side said it would work with India in jointly finding the treatment.

The sources said Modi, since his days as the Gujarat CM, has been trying to see if any solution could be found to the disease but has been helpless as no cure has been invented yet.

Sickle cell disease is a serious disorder in which the body makes sickle-shaped red blood cells. "sickle-shaped" means that the red blood cells are shaped like a crescent. Normal red blood cells are disc-shaped and look like doughnuts without holes in the center. They move easily through blood vessels. Red blood cells contain an iron-rich protein called hemoglobin. This protein carries oxygen from the lungs to the rest of the body.

Read more from the original source:
In Japan, Modi discusses sickle cell treatment with Nobel laureate

CU scientists' discovery could lead to new cancer treatment

PUBLIC RELEASE DATE:

29-Aug-2014

Contact: Kris Kitto kris@morethanpr.com 303-320-7790 The Bawmann Group

AURORA, Colo. (Sept. 2, 2014) A team of scientists from the University of Colorado School of Medicine has reported the breakthrough discovery of a process to expand production of stem cells used to treat cancer patients. These findings could have implications that extend beyond cancer, including treatments for inborn immunodeficiency and metabolic conditions and autoimmune diseases.

In an article published Aug. 29 in PLOS ONE, researchers from the Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology and Taiga Biotechnologies, Inc. said they have uncovered the keys to the molecular code that appear to regulate the ability of blood stem cells to reproduce and retain their stem-like characteristics.

The team developed protein products that can be directly administered to blood stem cells to encourage them to multiply without permanent genetic modifications.

"Use of stem cells to treat cancer patients who face bone marrow transplants has been a common practice for four decades," said Yosef Refaeli, Ph.D., an associate dermatology professor and one of the study's lead scientists. "The biggest challenge, however, has been finding adequate supplies of stem cells that help patients fight infection after the procedure."

Gates Stem Cell Center Director Dennis Roop, Ph.D., recognized the magnitude of the team's work.

"Researchers have long attempted to increase the number of blood stem cells in a lab," Roop said. "Most of those approaches have been limited by the nature of the resulting cells or the inadequate number of cells produced."

The technology described in the PLOS ONE article has worked with blood stem cells obtained from cord blood, adult bone marrow or peripheral blood from adults.

More:
CU scientists' discovery could lead to new cancer treatment

The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences …

Boston, MA (PRWEB) August 29, 2014

A major challenge before new biotechnology start-up companies, especially ones in the biotech start-up dense realm of Boston-Cambridge, is gaining visibility that can lead to important strategic alliances and able investors. James Sherley, the Director of Bostons Adult Stem Cell Technology Center, LLC (ASCTC), has made increasing the local and national visibility of his company an important priority since he started the company in September 2013.

In addition to a social media marketing campaign launched earlier in July of this year, Director Sherley has targeted research and development conferences both nationally and internationally to increase industry awareness of ASCTCs unique portfolio of intellectual property available for licensing and its current commercial development targets. The company is focused on producing two products to address two important needs in drug development and regenerative medicine, respectively, that it is uniquely positioned to address.

ASCTCs most advanced product is an assay that can detect, very early in the drug development pipeline, drug candidates that will ultimately fail because of their toxicity to tissue stem cells. ASCTC developed the new technology in partnership with AlphaSTAR, Corporation, located in Long Beach, California. Currently, such lurking drugs are not detected until after expensive animal testing, more expensive clinical trials, or worse, after marketing. Director Sherley refers to the second product as, A future of pounds and pounds of normal adult tissue stem cells. The company holds a patented technology for mass production of human tissue stem cells. The initial production target is human liver stem cells that can be used to make mature human liver cells for use in drug development and to support liver transplant patients. The company also holds patents for production of pancreatic stem cells and hair follicle stem cells.

The sponsor the 2014 Stem Cells & Regenerative Medicine Conference, in Boston, September 15-16, Terrapinn, Inc., invited ASCTC to attend as a VIP guest. Although ASCTC will not make a formal presentation at this conference, Director Sherley will participate in a roundtable discussion on the topic, Articulating value for up-and-coming regenerative medicine, stem cell and cell-based therapies.

Later in September (22-24), Director Sherley will present one of the selected Next Generation Presentations for new companies at BioPharm America 2014, also taking place in Boston. In addition to the public presentation, ASCTC will also participate in confidential partnering meetings with potential investors and strategic alliance partners arranged by conference organizers.

In October, Director Sherley will present to a primarily academic research audience a more detailed accounting of ASCTCs computer simulation technology for quantifying tissue stem cells in culture. This technology is the basis for the companys new assay for tissue stem cell toxicity. Director Sherley is particularly interested in the response from several experts in tissue stem cell growth dynamics who are invited speakers. The symposium, which will take place at Rhode Island Hospital, a medical affiliate of Brown University in Providence, has the goal of presenting emerging disruptive research in the area of Novel Stem Cells and Vesicles. Director Sherley is a member of the symposium organizing committee. ************************************************************************************************************* The Adult Stem Cell Technology Center, LLC (ASCTC) is a Massachusetts life sciences company established in September 2013. ASCTC Director and founder, James L. Sherley, M.D., Ph.D. is the foremost authority on the unique properties of adult stem cells. The companys patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing iPSCs. Currently, ASCTC is employing its technological advantages to pursue commercialization of mass-produced therapeutic human liver cells and facile assays that are early warning systems for drug candidates with catastrophic toxicity due to adverse effects against adult tissue stem cells.

Read the original:
The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences ...